Communiqués Eli Lilly and Company

Actions

LLY

US5324571083

Produits pharmaceutiques

Temps réel estimé Cboe BZX Autres places de cotation 20:21:54 10/06/2026			Varia. 5j.	Varia. 1 janv.
1 137,56 ^USD	-0,62%		+5,57%	+5,97%

14:08	Eli Lilly obtient l'approbation de la FDA pour une dose d'entretien d'EBGLYSS toutes les huit semaines dans le traitement de la dermatite atopique modérée à sévère	CI
12:03	Lilly maintient sa longueur d'avance face à l'offensive de ses concurrents sur le marché de l'obésité	RE

Communiqués

15:31	Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable	PR
00:20	FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis	PR
08/06	Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials	PR
07/06	Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause	PR
06/06	Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications	PR
03/06	Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association Annual Meeting	AQ
02/06	Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting	PR
01/06	Lilly's Retevmo demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer	AQ
31/05	Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer	PR
29/05	Eli Lilly and Company - Foundayo and Zepbound now covered for millions of Americans	AQ
28/05	Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care	PR
28/05	Foundayo and Zepbound now covered for millions of Americans	PR
27/05	Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference	PR
26/05	Lilly announces three acquisitions to build infectious disease portfolio	PR
25/05	A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia	PR
22/05	Eli Lilly and : Foundayo (orforglipron), a once-daily pill taken without food or water restrictions, was associated with reduced body weight by up to 13% in adults 65 and older with obesity or overweight, in new analysis of ATTAIN-1/2	PU
22/05	Obesity drug from Eli Lilly shows unprecedented weight loss in clinical trial	AQ
21/05	Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting	PR
21/05	Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial	PR
18/05	Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference	PR
16/05	Lilly, Caitlin Clark Foundation, and Musco Lighting open three community sports courts in Indianapolis, expanding year-round access for youth	PR
14/05	Lilly and UNICEF collaborate to give millions of children a healthier start	PR
13/05	Lilly's Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials	PR
12/05	In honor of its 150th anniversary, Eli Lilly and Company commits to support community organizations aiming to provide 500,000 meals and cold storage for 150 food pantries	PR
11/05	Eli Lilly To Acquire Kelonia Therapeutics	AQ